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Purpose: The transformation of quiescent keratocytes to active phenotypes and the ensuing fibrotic response play
important roles in corneal scar formation. This study aims to observe the antifibrotic effect of peroxisome proliferator-
activated receptor-γ (PPARγ) agonist on corneal fibroblasts cultured in vitro, and to explore the potential application of
peroxisome proliferator-activated receptor agonist to the prevention of corneal opacity following wound repair.
Methods: Rabbit corneal keratocytes were cultured in a medium containing 10% serum to induce their transformation to
fibroblasts and myofibroblasts, which are similar to those that repair corneas. After incubation with the PPARγ agonist
pioglitazone at different concentrations, the effect of pioglitazone on the migration, contractility, and viability of corneal
fibroblasts was examined. The secretion of matrix metalloproteinase-2 and matrix metalloproteinase-9 was determined
by gelatin zymography, and the synthesis of collagen I and fibronectin was investigated by western blotting.
Results: Treatment with pioglitazone at concentrations ranging from 1 to 10 μm significantly decreased corneal fibroblast
migration, as determined by scrape-wound assay, inhibited corneal fibroblast-induced collagen lattice contraction, and
reduced MMP-2 and MMP-9 secretion into the supernatant of cell cultures in a dose-dependent manner. The expression
of fibronectin was significantly decreased, while the expression of collagen I was only decreased when treated with 10
μm pioglitazone. Cell viability was not evidently changed compared to the control.
Conclusion: This in vitro study demonstrated the anti-fibrotic effect of pioglitazone, suggesting that activation of
PPARγ may be a new approach for the treatment of corneal opacity and scar formation in the corneal wound healing
process.
The  cornea  is  a  highly  specialized  transparent  tissue
located  at  the  anterior-most  surface  of  the  eye.  As  one
component of the refractive media, the transparency of the
cornea is very important for the maintenance of normal vision.
However, once the cornea is in an injured condition resulting
from,  for  example,  infection,  trauma,  and  surgery,  it  will
undergo a repair process involving an inflammation reaction
and  a  fibrotic  response,  which  usually  results  in  corneal
opacity and scar formation. According to an epidemiological
survey carried out in China, corneal scars have become the
primary reason for keratoplasty. Moreover, the occurrence of
haze following refractive surgery is believed to be related to
the  myofibroblasts  that  appear  during  the  wound  healing
process [1]. Therefore, research on how to reduce the corneal
scar formation by regulating the fibrotic response to injury
will be of great clinical value for the improvement of the visual
outcomes  of  patients  suffering  from  corneal  injury  or
receiving corneal surgery.
The  corneal  wound  healing  process  involves  a  very
complex and sometimes unpredictable biological response.
The  normally  quiescent  keratocytes  are  activated  and
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transformed  into  fibroblasts  and  myofibroblasts  under  the
stimulation of many inflammatory/fibrogenic growth factors
or cytokines such as TGFβ, CTGF, and so on [2-4]. This in
turn leads to increased extracellular matrix production, the
altered arrangement and contraction of collagen fibril [5,6],
and tissue remodeling of corneal stroma due to activation of
various  collagenases  and  other  proteases  [7,8].  Thus,
keratocytes and their active phenotypes, including fibroblasts
and  myofibroblasts,  play  central  roles  in  corneal  fibrotic
response and scar formation.
In recent years, many studies have demonstrated that
peroxisome  proliferator-activated  receptor-γ  (PPAR-γ)  is
involved in the anti-fibrotic effect in many tissues, such as the
kidney [9], liver [10], pancreas [11,12], lung [13], and heart
[14]. It is thought to be a promising target for the treatment of
fibrotic diseases. The aim of this work was to investigate the
effect of the PPARγ agonist, pioglitazone, on the function of
corneal fibroblasts cultured in vitro. We demonstrated that
pioglitazone  inhibited  cell  migration,  contractility,  matrix
metalloproteinase (MMP) secretion, and extracellular matrix
production, probably in a non-cytotoxic way, suggesting that
pioglitazone may exert a direct antifibrotic effect and have a
potential use in the treatment of corneal scar formation.
METHODS
Materials:  Dulbecco’s  Modified  Eagle’s  Medium,  fetal
bovine serum (FBS), and trypsin-EDTA were obtained from
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2279Invitrogen-Gibco (Carlsbad, CA); 6-well, 24-well, and 96-
well culture plates, as well as 25 cm2 cell culture flasks were
from  Corning  (Corning,  NY);  and  type  I  collagen  was
obtained from Shengyou Biotechnology Co., Ltd. (Hangzhou,
China).  Monoclonal  type  I  collagen  antibody,  fibronectin
antibody, and α-smooth muscle actin (α-SMA) antibody were
purchased  from  Abcam  (Cambridge,  UK).  Horseradish
peroxidase-conjugated secondary antibody and FITC-labeled
secondary antibody was purchased from Beijing Biosynthesis
Biotechnology  Co.,  Ltd  (Beijing,  China).  The  enhanced
chemoluminescence kit (20X LumiGLO® Reagent and 20X
Peroxide) was purchased from Cell Signaling Technology,
Inc.  (Beverly,  MA).  The  protein  assay  kit  (Quick  Start,
Bradford) was purchased from Bio-Rad (Hercules, CA). The
PPARγ agonist, pioglitazone, was purchased from Shandong
Zhongke  Taidou  Chemical  Co.,  Ltd.  (Jinan,  China).  All
reagent grade chemicals were from Sigma. Co. (St. Louis,
MO) unless otherwise indicated.
Corneal  fibroblast  culture:  Cultures  of  rabbit  corneal
fibroblasts  were  established  by  outgrowth  from  corneal
explants, as described previously [3]. Briefly, epithelial and
endothelial cells were removed from corneas, the stroma was
cut into cubes of approximately 1 mm3, placed in Dulbecco’s
Modified Eagle’s Medium containing 1 mM NaHCO3, and
buffered with 25 mM HEPES at pH 7.4. The medium was
supplemented with 10% heat-inactivated fetal bovine serum
and  antibiotics  (100  Units/ml  penicillin,  50  mg/ml
streptomycin-G). Cell cultures between passages 3 and 5 were
used for all experiments. The PPARγ agonist, pioglitazone,
was prepared as a 1 mM stock in dimethyl sulfoxide (DMSO)
and added to cell cultures to the final concentrations indicated.
DMSO  was  added  to  negative  control  wells  at  a  final
concentration of 0.1%. Cells were treated with pioglitazone at
the concentrations of 0.1, 1.0, 3.0, and 10 mM.
Immunofluorescence staining for α-SMA: To identify the cell
phenotype  transformation  of  the  keratocytes  cultured  in
serum-containing medium, immunofluorescence staining for
α-SMA was performed. Cells at the third passage were grown
on coverslips. The medium was removed, and the cell layer
was  rinsed  with  PBS.  Cells  were  fixed  with  4%
paraformaldehyde and permeabilized with triton-100 for 10
min  at  20  °C,  then  were  rehydrated  with  PBS,  and  then
blocked  with  5%  BSA  in  PBS  for  1  h.  Coverslips  were
sequentially incubated with monoclonal α-SMA antibody and
FITC-labeled secondary antibodies, each for 60 min at room
temperature. After washing, the nuclei were counterstained
with  DAPI.  Immunofluorescence  was  visualized  using  an
Olympus  microscope  and  recorded  with  a  high-resolution
Olympus  digital  camera.  Negative  control  was  performed
using nonimmune serum instead of the primary antibodies.
Cell viability assessment: The effect of pioglitazone on cell
viability was assessed by a 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium  bromide  (MTT)  assay.  Briefly,  the
corneal fibroblasts were seeded in a 96-well plate at a density
of 5,000/well and incubated for 24 h at 37 °C in a humidified
atmosphere of 5% CO2. Then the cells were treated with
pioglitazone at different concentrations (0.1, 1.0, 3.0, and 10
μm), using the culture medium by itself as a control. After a
24 h incubation, the MTT (5 mg/ml in PBS) was added to the
culture medium at the rate of 20 μl/well. After another 4 h of
incubation at 37 °C in 5% CO2, the media were removed and
the formazan crystals were solubilized with 100 ml DMSO
for 15 min. The optical absorbance was then measured at 570
nm on a microplate reader (Model 680 microplate reader, Bio-
Rad). For each concentration, the experiment was performed
in triplicate.
Collagen  gel  contraction  assays:  To  test  the  effect  of
pioglitazone on fibroblast contractility, another function of
fibroblasts,  fibroblast-mediated  gel  contraction  was
measured.  Collagen  gels  were  prepared  according  the
instructions from the manufacturer of the type I collagen.
Briefly,  sterile  type  I  collagen  solution,  distilled  water,
Dulbecco’s  Modified  Eagle’s  Medium,  and  fibroblast
suspensions were mixed by pipetting so that the final mixture
resulted in 1 mg/ml of collagen and 3×105 fibroblasts/ml gel.
A 300 μl portion of the gel solution was then cast into each
well  of  a  24-well  culture  plate.  Collagen  lattices  were
polymerized for 20 min in humidified 5% CO2 atmosphere at
37  °C,  then  incubated  with  Dulbecco’s  Modified  Eagle’s
Medium containing 10% FBS for 4 h, followed by overnight
incubation  in  serum-free  Dulbecco’s  Modified  Eagle’s
Medium. Pioglitazone was added into the culture medium at
different concentrations and incubated for 24 h. To initiate
collagen contraction, polymerized gels were gently released
from the underlying culture dish. To determine the degree of
collagen gel contraction, the area of each gel was recorded
photographically at day 1, 3, and 5 after release, and was
analyzed with Quantity One software (Bio-Rad). Data were
expressed as a percentage of the uncontracted gel size.
Scratch wound closure assays: Confluent cell monolayers in
a 6-well plate were wounded by mechanical scraping with a
pipette tip. Wound width was assessed at the time of scraping
to ensure that all wounds were the same width at the start of
the experiments. The cell culture medium was then replaced
with fresh medium, with or without pioglitazone treatment,
and wound closure was recorded photographically over time,
using phase-contrast microscopy.
Gelatin zymography: Confluent cells grown in 96-well plates
were exposed to pioglitazone at different concentrations for
72 h. The culture supernatants were harvested at 72 h and
mixed with gel sample buffer. Equal volumes were loaded
onto a 10% SDS polyacrylamide gel that contained 1 mg/ml
gelatin,  and  were  subjected  to  electrophoresis.  After
electrophoresis, the gels were washed in 50 mM Tris buffer
that contained 2.5% Triton X-100. The gels were incubated
for an additional 40 h in 50 mM Tris buffer (pH 7.6) that
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Coomassie  blue  and  subsequently  destained  in  methanol/
acetic acid/H2O. Gels were scanned, and density analysis of
the bands was performed using Quantity One software.
Western  blot  analysis  for  collagen  I  and  fibronectin:
Confluent cells grown in 6-well plates were exposed to either
no pioglitazone (control) or pioglitazone at the concentration
of 1, 3 and 10 μm for 72 h. For extracting protein from cell
lysates, cells first were washed twice with PBS. They were
then lysed in lysis buffer that contained 50 mM Tris-HCl (pH
7.4),  150  mM  NaCl,  0.2  g/l  sodium  azide,  5  g/l  sodium
deoxycholate, 100 mg/l phenylmethyl sulfonylfluoride, 0.1%
SDS, 1% NP-40 and proteinase inhibitor aprotinin (2 mg/l;
Amresco Inc., Solon, OH), and leupeptin (2 mg/l; Amresco
Inc.)  for  20  min.  This  was  followed  by  centrifugation  at
12,000× g for 10 min at 4 °C. Protein concentrations were
determined by the Bradford method using a protein assay kit.
Protein (50 μg) from cell lysates was mixed with sample
buffer,  separated  on  10%  SDS  polyacrylamide  gels,
transferred to nitrocellulose membranes (Pall Life Sciences,
East Hills, NY) and then blocked overnight at 4 °C in TBS
containing 5% defatted milk powder and 0.1% Tween 20. The
membranes  were  probed  with  either  specific  anti-type  I
collagen  and  anti-fibronectin  primary  antibodies,  and
subsequently  washed  with  TBS-T  and  incubated  with  the
secondary antibodies conjugated with horseradish peroxidase
for 1 h at room temperature. GAPDH immunoblotting was
performed  as  an  internal  control  for  equal  loading.  After
extensive washing in TBS-T, the blots were developed for 30
to  60  s  with  enhanced  chemiluminescence  reagents.  All
reagent grade chemicals were from Sigma. Co. (St. Louis,
MO) unless otherwise indicated.
Statistical analysis: Values are means±SD from three to six
samples. Comparisons between two groups were analyzed
using Student’s t test, and among three groups by ANOVA,
followed by a post hoc comparison using the least significant
difference test (SPSS 11.5). Values of p<0.05 were considered
statistically significant.
RESULTS
Transformation  of  keratocytes  to  fibroblasts  and
myofibroblasts: The cells, observed with an inverted phase-
contrast  microscope,  exhibited  a  uniform  fibroblast-like
shape. Most of the cells were positive for α-SMA staining by
immunocytochemistry  (Figure  1A).  A  negative  control
(normal  nonimmune  serum  was  used  instead  of  primary
antibody)  showed  no  positive  staining  (Figure  1B),
demonstrating that the cells we used for the experiment were
mainly myofibroblasts.
Pioglitazone  inhibits  fibroblast  motility:  The  effects  of
pioglitazone on corneal fibroblast migration were assessed by
scrape-wound  assay.  As  shown  in  Figure  2A,
photomicrographs taken 24, 48, and 72 h after wounding
showed delayed wound closure by corneal fibroblast cultures
treated with pioglitazone at concentrations ranging from 1 to
10 μm compared with untreated control cultures. Quantitation
of  the  wound  closure  over  time  revealed  a  significant
inhibitory effect of pioglitazone on corneal fibroblast motility
(Figure 2B) at even the lowest concentration of pioglitazone
(1 μm).
Pioglitazone reduces fibroblasts’ capacity to contract free-
floating  collagen  lattices:  To  determine  the  effect  of
pioglitazone  on  ECM  contraction  induced  by  fibroblasts,
corneal fibroblasts were seeded in free-floating collagen gels
Figure 1. Expression of α-smooth muscle actin in corneal myofibroblasts. The third passage corneal fibroblasts cultured on coverslips were
washed with PBS, fixed with 4% paraformaldehyde, blocked in BSA/PBS, and sequentially incubated with monoclonal α-smooth muscle
actin and FITC-conjugated secondary antibody. The nuclei were counterstained with 4'-6-diamidino-2-phenylindole(DAPI). Negative controls
were  performed  using  nonimmune  serum  instead  of  primary  antibodies.  A:  Co-localization  of  α-SMA  (green)  and  nuclei  (blue)  in
myofibroblasts. B: Negative control.
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kinetics of collagen lattice contraction were then recorded
over a 5 d period. Results demonstrated that pioglitazone had
a potent dose-dependent inhibitory effect on collagen lattice
contraction  by  corneal  fibroblasts,  especially  at  the
concentration of 10 μm, as shown in Figure 3. At day 5,
pioglitazone  treatment  at  concentrations  of  3  and  10  μm
resulted in significantly greater lattice diameters, relative to
the control.
The effect of pioglitazone on MMP-2 and MMP-9 secretion:
After exposure to pioglitazone at different concentrations,
there was a decrease in the cellular secretion of both MMP-9
and MMP-2, detected by gelatin zymography, as shown in
Figure 4. MMP-9 activity was reduced by 41%, 48%, and
74%,  and  MMP-2  was  reduced  by  11%,  47%,  and  65%,
compared with the control after treatment with pioglitazone
at the concentrations of 1, 3, and 10 μm, respectively.
Effect  of  pioglitazone  on  type  I  collagen  and  fibronectin
expression: To determine the effect of PPARγ agonists on
corneal fibroblast production of collagen I and fibronectin,
cells were treated with pioglitazone, and western blotting was
performed  to  detect  the  expression  of  collagen  I  and
fibronectin. As shown in Figure 5, the results indicated that
fibronectin protein expression was reduced by pioglitazone in
a dose-dependent manner, while collagen I synthesis was only
significantly reduced at a relatively high concentration of
pioglitazone (10 μm).
Pioglitazone has no evident effect on the viability of corneal
fibroblasts: To exclude the possibility that the anti-fibrotic
effect of pioglitazone was mediated by cellular toxicity, MTT
assay was used to examine the viability of corneal fibroblasts
after treatment with pioglitazone at different concentrations.
Viable cells actively cleave the MTT reagent and form a
colored precipitate, the appearance of which is proportionate
to  the  number  of  viable  cells.  Results  are  expressed  as  a
Figure  2.  Effect  of  plioglitazone  on
corneal  fibroblast  cell  motility.  A
monolayer  of  confluent  corneal
fibroblasts  was  scraped  with  a  sterile
pipette tip after being preincubated with
increasing  concentrations  of
pioglitazone (1, 3, and 10 μm) for 24 h.
Wound closure was observed by phase-
contrast microscopy and photographed
at 0, 24, 48, and 72 h. A: Photographs of
one  representative  experiment.  B:
Graphic representation of the mean of
four experiments. For each sample, the
result is expressed as percentage of the
wound  width  at  the  start  of  the
experiment.  The  asterisk  indicates
p<0.05 versus the control group
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ability of corneal fibroblasts to contract
free-floating collagen lattices. Corneal
fibroblasts were seeded in collagen gel
lattice  in  the  absence  or  presence  of
pioglitazone at the concentrations of 3
and  10  μm.  Cell  contractility  was
assessed by measuring the reduction in
the surface area of the floating collagen
gel discs for the times shown (1–5 d).
A:  Photographs  of  one  representative
experiment. B: Graphic representation
of the mean±SD of three experiments.
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As shown in the Figure 6, there was no significant difference
in cell viability between the pioglitazone treated group and the
control. This suggests pioglitazone might exert its antifibrotic
effect in a non-cytotoxic way.
DISCUSSION
The  cornea  is  composed  of  three  tissue  layers:  the  outer
stratified squamous epithelium, the inner endothelium, and
the intermediate stroma. The stroma makes up 90% of the
corneal thickness. It is comprised of collagen fibers that are
arranged in bundles, and of sparsely distributed stromal cells
that are referred to as keratocytes. This particular structure is
the  basis  for  the  maintenance  of  corneal  transparency.
However, various kinds of injuries, including inflammatory
reactions and fibrotic responses, will destroy the homeostasis
of  the  cornea  and  induce  the  repair  process.  It  must  be
emphasized that although corneal fibrosis is very important
for  the  healing  of  injured  corneas,  over-reactive  fibrosis
usually  gives  rise  to  many  undesirable  effects.  Previous
research has shown that corneal fibrosis can lead to loss of
transparency to different extents, due to the lack of precise
organization, and to molecular changes in the repair tissue and
cells. It can also result in changed corneal shape, due to repair
tissue contraction.
So far, there is no effective and safe strategy for the
prevention or inhibition of corneal scar formation in clinical
practice.  Corticosteroid  is  now  widely  used  for  its  anti-
inflammatory effect, and it does have a significant inhibitory
effect  on  fibrotic  reactions.  However,  it  is  generally
recognized that it can be hardly used in the acute phase of
infection because of its suppression of the immune system. It
Figure  4.  Detection  of  MMP-2  and
MMP-9  by  gelatin  zymography.
Treatment  with  pioglitazone  at
concentrations  of  1,  3,  and  10  μm
resulted  in  significant  decreases  in
MMP-2  and  MMP-9  secretion.  A:  A
representative  zymogram  is  shown.
Lane 1, control; lane 2, 1 μm; lane 3, 3
μm; lane 4, 10 μm. B: The densitometric
values of the MMP-9 and MMP-2 bands
are  expressed  as  percentages  of  the
control.  Results  are  the  mean±SD  of
three  independent  experiments  (the
asterisk  indicates  p<0.05  versus
control),  indicating  a  dose-dependent
inhibition  of  pioglitazone  on  MMP-9
and MMP-2 secretion.
Figure  5.  Effect  of  pioglitazone  on
collagen I and fibronectin expression.
The  expression  of  collagen  I  and
fibronectin by corneal fibroblasts was
analyzed  by  western  blotting  after
treatment with or without pioglitazone
(1, 3, and, 10 μm). A: Representative
immunoblot  for  collagen  I  and
fibronectin. Lane 1, control; lane 2, 1
μm; lane 3, 3 μm; lane 4, 10 μm. B:
Quantitative analysis of collagen I and
fibronectin  protein  expression  by
densitometry from cells described in A.
Values  are  the  means±SD  from  three
separate  experiments.  The  asterisk
indicates p<0.05 compared with control.
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Therefore, we should explore novel approaches to regulating
fibrotic reactions during the corneal repair process.
Peroxisome  proliferator-activated  receptors  (PPARs)
comprise a family of ligand-activated transcription factors
belonging to the nuclear hormone receptor family. They are
related  to  retinoid,  glucocorticoid,  and  thyroid  hormone
receptors [15]. There are three subtypes, PPARα, PPARβ, and
PPARγ, with a wide range of effects on metabolism, cellular
proliferation, and immune responses [16,17]. PPARs were
first identified in their role in lipid and glucose regulation, and
until recently, many research studies have demonstrated that
PPARs  have  anti-fibrotic,  anti-inflammatory,  and  other
important functions. Fibrosis-related diseases are involved in
almost all connective tissues, and share common pathological
characteristics. Fibrosis in many tissues, such as the kidney,
liver, lung, heart, and pancreas, has been demonstrated by
experiments  to  be  inhibited  by  the  activation  of  PPARγ.
Moreover, fibrosis in ocular tissues, including corneal fibrosis
and conjunctival fibrosis, has also been demonstrated to be
suppressed by PPARγ activation in animal models [18,19].
However, the cellular and molecular mechanism of the anti-
fibrotic action of PPARγ activation in corneal tissue is not yet
well understood.
To investigate the mechanism by which PPARγ agonist
exerts  an  anti-fibrotic  effect  on  corneal  fibrosis,  we  took
corneal keratocytes cultured in a serum-containing condition
as an in vitro model of corneal wound healing. The phenotypic
transition from keratocyte to repair cell in corneal wounds is
similar to the change that occurs when keratocytes are isolated
from the normal stroma, placed in a cell culture, and exposed
to serum [20,21]. The transition is characterized by a change
in cell shape, exhibiting many morphological characteristics
of fibroblasts, including a fusiform shape, multiple nucleoli,
and a lack of cytoplasmic granules [22].
In  our  study,  pioglitazone  was  shown  to  inhibit  the
corneal fibroblast migration, and to reduce their capacity to
contract free-floating collagen lattices, which is thought to be
related to the expression of α-SMA. Moreover, the secretion
of MMP-2 and MMP-9 in the supernatant of cell cultures
decreased  after  the  subministration  of  pioglitazone.  The
MMPs  are  believed  to  play  an  important  role  in  corneal
remodeling after wounding, through its critical effect on the
balance between matrix degradation and production. Collagen
I  and  fibronectin  are  the  major  components  of  corneal
extracellular  matrices,  the  expression  of  which  clearly
increases during the process of wound healing. Our results
show pioglitazone significantly inhibited the expression of
fibronectin, but only had an inhibitory effect on collage I
expression at a relatively high concentration. We can therefore
deduce  that  PPARγ  activation  might  influence  the
extracellular matrix turnover in two different aspects: those
involving production and degradation.
Cell  viability  assay  in  this  study  suggested  that  the
antifibrotic effect of pioglitazone might operate in a non-
cytotoxic manner. The signaling pathway in the antifibrotic
action of PPARγ activation is still not entirely understood. Li
et al. [23] proved that hepatocyte growth factor (HGF) is a
downstream effector that mediates the antifibrotic action of
peroxisome proliferator–activated receptor-γ agonists in their
study on renal fibrosis lesions. In addition, several research
studies have demonstrated that crosstalk between PPARγ and
TGF-β1, Smad2/3, and JNK signaling pathways is critical for
the suppression of Ang II-induced production of PAI-1 and
ECM [24,25].
It must be pointed out that there exist several limitations
to this study. Our study has demonstrated the anti-fibrotic
effect of the PPARγ agonist on cultured corneal fibroblasts in
vitro, which is similar to the active phenotype in the corneal
repair process. However, what effect might it have on the
transformation of keratocyte to fibroblast or myofibroblast?
This is the topic of research that we are now investigating;
moreover, the in vivo effect of PPARγ activation remains to
be further investigated.
Overall,  our  results  demonstrate  that  pioglitazone,  a
PPARγ activator, has an evident anti-fibrotic effect on corneal
fibroblasts,  cultured  in  vitro,  by  such  mechanisms  as
suppression of cell motility, contraction, and expression of the
Figure 6. Cell viability is not influenced
by  treatment  with  pioglitazone.  After
treatment with medium alone, or with
pioglitazone at 0.1, 1, 3, and 10 μm,
respectively, for 72 h, the viability of
corneal  fibroblasts  was  measured  by
MTT  assay.  Results  are  shown  as
percentages  of  the  control  (untreated
cells).  There  was  no  significant
difference  between  any  treatment
(ANOVA) p>0.05 versus control.
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data are exciting, and suggest that the PPARγ pathway is likely
a very important future target for corneal fibrosis therapy, and
that it might be used to attenuate scar formation during the
corneal repair process.
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